BiomX Inc.

For the period ended Dec 31, 2025. Filed Feb 19, 2026.

About this filing

A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.

FY2025 · Filed Feb 19, 2026

HLSQ$0.07-37.4%Stored close · as of Nov 10, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents

Item 8. Consolidated Statements of Cash Flows

CONSOLIDATED STATEMENTS OF CASH FLOWS

	Year ended December 31,
	2025	2024
CASH FLOWS – OPERATING ACTIVITIES
Net loss	(36,199)	(17,727)
Adjustments required to reconcile net loss to cash flows used in operating activities
Depreciation	2,922	1,803
Stock-based compensation	2,091	1,848
Gain from early lease termination	(2,949)	-
Finance expense (income), net	256	(435)
Revaluation of contingent consideration	(77)	(78)
Income from change in fair value of warrants	(6,111)	(26,458)
Private Placement Warrants issuance cost	-	732
Changes in contract liability	-	(1,976)
Loss from sale and disposal of fixed assets, net	205	221
Goodwill impairment	-	801
IPR&D impairment	11,842	3,237
Other long-lived asset impairment	1,653	4,046
Changes in operating assets and liabilities:
Other current assets	2,243	842
Trade account payables	1,238	(3,167)
Other account payables	(3,430)	(984)
Net change in operating leases	(74)	316
Net cash used in operating activities	(26,390)	(36,979)
CASH FLOWS – INVESTING ACTIVITIES
Cash and restricted cash acquired from the APT acquisition	-	663
Purchase of property and equipment	(2)	(30)
Proceeds from sale of property and equipment	110	82
Net cash provided by investing activities	108	715
CASH FLOWS – FINANCING ACTIVITIES
Issuance of Common Stock under February 2025 SPA	996	-
February 2025 SPA issuance costs	(118)	-
Issuance of Common Warrants under February 2025 SPA	4,531	-
Issuance of Common Stock under Inducement Letter Agreements	6,473	-
Pre-Funded Warrants exercise	2	6
Issuance of Common Stock under Open Market Sales Agreement, net of issuance costs	1,305	19
Repayment of long-term debt	-	(10,747)
Issuance of Private Placement Warrants under March 2024 PIPE	-	28,745
Issuance of Redeemable Convertible Preferred Shares under March 2024 PIPE	-	21,269
March 2024 PIPE issuance costs	-	(918)
Net cash provided by financing activities	13,189	38,374
Increase (decrease) in cash and cash equivalents and restricted cash	(13,093)	2,110
Effect of exchange rate changes on cash and cash equivalents and restricted cash	73	1
Cash and cash equivalents and restricted cash at the beginning of the year	17,975	15,864
Cash and cash equivalents and restricted cash at the end of the year	4,955	17,975

**CONSOLIDATED STATEMENTS OF CASH FLOWS

	Year ended December 31,
	2025	2024
RECONCILIATION OF AMOUNTS ON CONSOLIDATED BALANCE SHEETS:
Cash and cash equivalents	4,360	16,856
Restricted cash	595	1,119
Total cash and cash equivalents and restricted cash	4,955	17,975
SUPPLEMENTAL DISCLOSURE OF CASH FLOW INFORMATION:
Cash paid for interest	20	1,442
Taxes paid in Israel	7	13
SUPPLEMENTAL DISCLOSURE OF NON-CASH INVESTING ACTIVITIES:
Lease liability and Operating lease right-of-use asset remeasurement	2,487	-
Derecognition of right-of-use asset as a result of operating lease termination	1,799	-
Derecognition of lease liability as a result of operating lease termination	4,902	-
Property and equipment purchases included in accounts payable	-	1
Issuance cost from March 2024 PIPE	-	1,273
Issuance of Common Stock under the APT acquisition	-	3,041
Issuance of Redeemable Convertible Preferred Shares under the APT acquisition	-	12,610
Issuance of Merger Warrants under the APT acquisition	-	200
Redeemable Convertible Preferred Shares conversion into shares of Common Stock	28	13,774

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.